Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

WHO To Recommend Countries Stop Testing For H1N1
Within the next few days, the WHO "will recommend that countries stop trying to test all suspected cases of swine flu, said Keiji Fukuda, the agency"s assistant director-general of health security and environment," Tuesday during a conference call with reporters, Bloomberg reports. Instead, countries who have previously confirmed cases of the H1N1 virus in their population should diagnose the flu based on symptoms alone, opening up "laboratories to test samples in unusual or severe cases, clusters of illnesses and cases with odd symptoms, he said," Bloomberg writes (Serafino/Hallam, 7/7).
generic viagra online
Data Published In The New England Journal Of Medicine Support Use Of Raxibacumab (ABthrax(TM)) For The Treatment Of Inhalation Anthrax
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company"s human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease.
News of the day
Antiabortion-Rights Advocate To Oversee HHS Office Of Faith-Based And Community Partnerships
President Obama has named Alexia Kelley -- Catholics in Alliance for the Common Good co-founder and former executive director -- to the position of director of Faith-Based and Community Partnerships at HHS, Salon"s "War Room" reports. According to Salon"s the "War Room," CACG primarily has worked to find ways to reduce the demand for abortion procedures rather than advocate for laws to restrict access. However, CACG"s Web site reads, "Catholics in Alliance believes in the sanctity of all human life -- from conception until natural death" (Madden, "War Room," Salon, 6/4).Catholics for Choice President Jon O"Brien writes in The Hill"s "Congress Blog" that the appointment is "a defeat for reason and logic" and "calls into question whether President Obama"s administration is serious about reducing the need for abortion." According to O"Brien, Kelley "is on record with her support for restrictions on access to abortion," although CACG has sought to "avoid the question of legalization at every turn." O"Brien continues that the group also used "flawed economic data to support anti-poverty measures as a means to reduce the number of abortions," and "opposed evidence-based prevention methods such as contraception and comprehensive sexuality education" (O"Brien, "Congress Blog," The Hill, 6/4).Officials at the White House and HHS did not return calls for comment. CACG spokesperson Jennifer Goff said, "Catholics in Alliance for the Common Good is working toward reaching common ground in order to make real progress on the moral and political challenges our country faces instead of resorting to spurious attacks launched by those who are more concerned with inflaming the culture wars than effecting positive change" ("War Room," Salon, 6/4).
Public Health

B. Braun Anticipates Becoming First To Deliver FDA Approved 2g Cefazolin

B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, said today it anticipates U.S. Food and Drug Administration (FDA) approval for 2g Cefazolin for Injection USP and Dextrose Injection USP in B. Braun"s DUPLEX(R) Drug Delivery System. The FDA approval will make B. Braun the first company to deliver an FDA approved 2g Cefazolin dose to hospitals and other healthcare settings where it is a frequently prescribed antibiotic. The arrival of 2g Cefazolin will be welcome news in hospital emergency rooms, operating suites and outpatient surgical centers. Until now, Cefazolin had only been available in 1g IV and multi-dose vials. The 2g Cefazolin in the DUPLEX(R) system can be stored, ready to use wherever and whenever it is needed, which means faster, safer and more accurate administration of 2g Cefazolin to patients. "B. Braun heard physician and pharmacist calls for a 2g Cefazolin dose and we"ve responded," said Rob Albert, Vice President, Pharma Marketing for B. Braun. "2g Cefazolin will be the latest in an expanding DUPLEX(R) portfolio, which is designed to provide fast, safe, convenient and Joint Commission and USP Chapter compliant products that improve the practice of healthcare professionals while advancing patient safety and outcomes." Frequently used in emergency rooms, operating suites and ambulatory surgery centers, B. Braun will offer 2g Cefazolin delivered via its DUPLEX(R) Delivery System, a ready-to-use two-compartment flexible plastic IV container that stores pre-measured drug and diluent doses. Healthcare workers administering DUPLEX(R) simply squeeze the container and shake it to mix pharmaceuticals and diluent. The DUPLEX(R) system saves time, labor and speeds dispensing because it can be stored right in emergency and operating rooms until it"s needed and is ready immediately. Its PVC-free construction makes it eco-friendly while its DEHP-free and Latex-free construction makes it patient-friendly. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking. With the addition of 2g Cefazolin to its drug delivery portfolio, B. Braun will expand its broad spectrum of intravenous cephalosporin antibiotic therapies for the hospital setting: Cefoxitin, CefTRIaxONE, 1g Cefazolin, CefUROXime and Cefotetan. About DUPLEX The DUPLEX(R) Drug Delivery System is a revolutionary system designed to simplify intravenous antibiotic delivery to patients, minimize the potential for medication errors, eliminate the pharmacy labor component of IV antibiotic delivery and reduce drug waste. Consisting of a pre-filled, DEHP-free, PVC-free, Latex-free IV bag containing proper doses of drug and diluent in different compartments separated by a quick release seal, DUPLEX(R) can be stored at room temperature and does not require a messy thawing process. The caregiver simply squeezes the bag to mix the drug and diluent just prior to administration. Special oxygen and moisture barrier technologies are employed to protect the drug powder from vapor and oxygen transfer through the bag over the product"s shelf life. About B. Braun B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company"s "Sharing Expertise(R)" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives. Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. Braun Medical Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009